Screener
Neurocrine Biosciences NBIX Business Segments — Unrealized gain (loss) on equity investments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss.
The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000914475-26-000026
| (in millions) | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Total research and development | 296.2 | 263.2 |
| Acquired in-process research and development | 21.2 | 0.1 |
| Selling, general, and administrative | 318.5 | 276.5 |
| Gain on sale of business, net of transaction costs | (28.6) | — |
| Unrealized (gain) loss on equity investments | (25.3) | 30.6 |
| Investment income and other, net | (28.1) | (21.7) |
| Provision for income taxes | 48.9 | 6.8 |
| Net income | $197.9 | $7.9 |
Item 1. Financial Statements
FAQ
- What is Neurocrine Biosciences's business segments — unrealized gain (loss) on equity investments?
- Neurocrine Biosciences (NBIX) reported business segments — unrealized gain (loss) on equity investments of $25.3M in Q1 2026.
- How has Neurocrine Biosciences's business segments — unrealized gain (loss) on equity investments changed year-over-year?
- Neurocrine Biosciences's business segments — unrealized gain (loss) on equity investments increased by 182.7% year-over-year, from -$30.6M to $25.3M.
- What is the long-term trend for Neurocrine Biosciences's business segments — unrealized gain (loss) on equity investments?
- Over 2 years (2022 to 2024), Neurocrine Biosciences's business segments — unrealized gain (loss) on equity investments has grown at a 9.8% compound annual growth rate (CAGR), from $30.8M to -$37.1M.
- What does business segments — unrealized gain (loss) on equity investments mean?
- Captures the change in market value of the company's minority equity holdings in other entities. This reflects the performance of the company's strategic investment portfolio rather than core operations.
Ask your AI about Neurocrine Biosciences's business segments — unrealized gain (loss) on equity investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude